Dr. Moul on Challenges With Sequencing Therapies for Prostate Cancer

Video

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.

The biggest challenge faced, Moul explains, often occurs when a patient has metastatic castration-resistant prostate cancer. Often, Moul starts a treatment plan with sipuleucel-T (Provenge); however, it is unclear whether patients should subsequently receive enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Both are novel, hormonal therapeutic agents that urologists should be comfortable prescribing to patients. Treatment should be individualized to each patient, Moul adds.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,